Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
SPIRIVA in Ususal Care
The objective of the study is to determine the effect on lung function when either SPIRIVA once daily or placebo once daily is added to the usual therapy (care) of COPD patients naïve to anticholinergic agents managed in primary…
- Trial name
- NCT00274079
- Testing
- SPIRIVA
- Where
- 44 sites in United Kingdom
- Volunteers
- 395 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT01040689
- Testing
- Olodaterol (BI1744) Low, Olodaterol (BI1744) High, Tiotropium 18 mcg
- Where
- 15 sites in Belgium, Denmark and 2 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
The purpose of this study is to assess the tolerability and efficacy of inhaled theophylline (ADC4022) on markers of pulmonary inflammation (white blood cells) in induced sputum and in bronchial biopsy samples in subjects with…
- Trial name
- NCT00634413
- Testing
- Theophylline - ADC4022, Budesonide
- Where
- 8 sites in Poland, United Kingdom
- Volunteers
- 91 people
- Sponsor
- Pulmagen Therapeutics
Pulmonary Disease, Chronic Obstructive
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
Optimal clinical management in early stages of COPD is not established. Tiotropium has been shown to improve exercise tolerance during (CWR) cycle ergometry with GOLD stage II to IV COPD, improvements in constant speed treadmill…
- Trial name
- NCT01072396
- Testing
- Tiotropium
- Where
- 15 sites in United States, Canada
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00880490
- Testing
- Inhaled PT005, Formoterol Fumarate 12 mcg (Foradil Aerolizer)
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 34 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging
The goal of this clinical trial is to compare responses to bronchodilator treatment delivered by three different aerosol delivery methods in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT06271408
- Testing
- Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Polarean, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Chronic Obstructive Pulmonary Disease
Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS
This study is to evaluate if add-on treatment with inhaled NVA237 (50 µg) once daily (o.d.) via single-dose dry-powder inhaler (SDDPI) further improves lung function and health status and is well tolerated compared to placebo in…
- Trial name
- GLOW8 (NCT01757015)
- Testing
- NVA237
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Assessment of Treatment With PulseHaler on Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to assess the safety and the effect of treatment by PulseHaler™ on patients with COPD, as measured by the change from baseline in full pulmonary functions, oxygen saturation, exercise tolerance and…
- Trial name
- NCT00821418
- Testing
- PulseHaler treatment, CPAP treatment (through a deactivated version of PulsHaler)
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Respinova LTD
COPD, Pulmonary Hypertension
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of long term iNO administrationusing the…
- Conditions
- COPD, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03135860
- Testing
- Inhaled Nitric Oxide 30mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bellerophon
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation…
- Trial name
- NCT06748079
- Testing
- TQC3721 inhalation powder, TQC3721 inhalation powder combined with glyberlam inhalation powder or a control group
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the safety and preliminary performance of the ROX Anastomotic Coupler System (ACS), with standard of care (as defined per GOLD) in patients with Chronic Obstructive Pulmonary Disease…
- Trial name
- NCT00992680
- Testing
- ROX Anastomotic Coupler System (ACS)
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- ROX Medical, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of an investigational medication used to treat chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT02772159
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The safety, tolerability, pharmacokinetics and pharmacodynamics/efficacy profiles of two different doses of GSK233705 will be compared with 2 active comparators and placebo, all medication delivered via dry powder inhaler.
- Trial name
- NCT00422604
- Testing
- salmeterol, tiotropium, GSK233705
- Where
- 11 sites in Finland, Germany and 3 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study will evaluate the safety and efficacy of QVA149 in patients with moderate to severe COPD.
- Trial name
- NCT00570778
- Testing
- indacaterol/glycopyrrolate, indacaterol
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
RELOVAIR® Lung Deflation Study
The primary objective of the study is to test the hypothesis that lung hyperinflation contributes to cardiac dysfunction in COPD and that the treatment of lung deflation with FF/VI Inhalation Powder 100/25 mcg administered once…
- Trial name
- NCT01691885
- Testing
- Fluticasone Furoate, Vilanterol
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
- Trial name
- LABD (NCT00791518)
- Testing
- No intervention
- Where
- 57 sites in United States
- Volunteers
- 1,084 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Noninvasive Ventilation
Determination of the Prevalence and Severity of Expiratory Flow Limitation in Chronic Obstructive Pulmonary Disease Patients
Expiratory Flow Limitation (EFL) occurs when the airways become compressed, which usually results when the pressure outside the airway exceeds the pressure inside the airway.
- Trial name
- NCT03851510
- Testing
- Vector ventilator, Resmon Pro
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Philips Respironics
Pulmonary Disease, Chronic Obstructive
12 / 48 wk Pivotal PFT vs PBO in COPD II
This primary objective of this study is to compare two doses of BI 1744 CL inhalation solution delivered by the Respimat® inhaler once daily to placebo in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00782509
- Testing
- Olodaterol (BI 1744)
- Where
- 51 sites in United States, China and 2 more
- Volunteers
- 644 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.